1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO
Thermo Fisher Scientific Inc.US flagNew York Stock Exchange
469.63
USD
-3.17
- -
174.52BMarket Cap
Thermo Fisher Scientific Inc.
TMO
(New York Stock Exchange)

Recent

price

469.63

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
25.77
30.35
34.39
36.33
42.41
42.55
46.29
52.96
60.59
63.86
81.36
99.52
114.58
111.03
112.25
118.19
120.2
Revenue per Share
2.57
3.49
3.24
3.53
4.76
4.95
5.12
5.63
7.31
9.24
16.1
19.61
17.73
15.53
16.58
17.78
18.21
Basic EPS, GAAP
3.07
3.76
4.74
4.8
5.5
6.32
7.13
8.85
9.42
10.12
17.21
17.23
17.63
17.95
19.02
16.69
17.95
Free Cash Flow per Basic Share
- -
- -
0.39
0.6
0.59
0.6
0.6
0.6
0.66
0.74
0.85
1
1.16
1.35
1.53
1.69
1.73
Dividend per Share
14.35
18.7
22.29
25.32
27.16
31.49
36.33
41.37
47.58
56.32
72.1
91.04
108.04
123.85
140.17
158.09
162.44
Book Value per Share
1.12
-12.48
-13.23
-7.55
-31.15
-25.67
-34.85
-41.93
-31.69
-25.13
-10.63
-53.45
-36.96
-35.88
-30.66
-30.94
-59.23
Tangible Book Value per Share
403
381
364
360
398
399
395
395
402
400
396
394
392
386
382
377
376
Basic Weighted Avg Shares
10,393
11,559
12,510
13,090
16,890
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
45,196
Sales/Revenue/Turnover
12.01
11.66
12.5
12.89
11.28
14.45
14.49
14.61
15.74
16.37
24.5
26.08
18.94
17.08
18
18.2
18.16
Operating Margin (%)
746
860
984
1,000
1,685
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
2,811
Depreciation Expense
1,036
1,330
1,178
1,273
1,894
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,704
6,848
Net Income, GAAP
9.34
9.66
0.87
3.06
9.18
- -
- -
8.28
9.93
9.18
11.76
12.54
8.97
4.51
9.34
7.48
7.03
Effective Tax Rate (%)
9.96
11.51
9.42
9.73
11.22
11.64
11.06
10.64
12.06
14.47
19.79
19.7
15.47
13.99
14.77
15.05
15.15
Profit Margin (%)
2,425
1,709
2,742
6,755
1,190
1,595
2,155
2,373
4,478
5,696
11,653
6,677
8,219
10,577
8,805
13,518
7,695
Working Capital
2,031
5,755
7,031
9,500
12,352
11,420
15,372
18,873
17,719
17,076
19,107
32,333
28,909
31,308
29,061
35,852
40,071
LT Debt
15,361
15,038
15,465
16,856
20,548
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,672
53,536
52,061
Total Equity
6.44
6.16
6.96
6.57
5.54
- -
- -
6.63
7.44
8.1
13.47
13.57
10.05
8.73
8.62
8.65
8.54
Return on Invested Capital (%)
14.95
13.48
9.65
8.77
10.36
- -
- -
8.1
9.38
10.99
15.15
13.51
10.28
9.19
9.05
8.69
8.47
Return on Capital (%)
19.61
20.6
15.46
14.78
19
16.9
15.04
14.5
16.57
17.75
24.96
23.98
17.77
13.3
12.5
11.85
11.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3,823
3,533
3,090
LT Borrowings
31,857
35,852
40,071
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
376
376
372
Market Capitalization
183,823
218,742
184,815

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
22,295
28,707
22,316
Cash, Cash Equivalents & STI
3,546
10,105
3,256
Accounts Receivable, Net
8,911
8,900
9,204
Inventories
5,745
5,425
5,496
Total Current Liabilities
14,888
15,189
14,621
Payables & Accruals
8,213
8,946
8,603
ST Debt
3,823
3,533
3,090
Deferred Revenue
2,852
2,710
2,928

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
9.28%
7.78%
Free Cash Flow
11.27%
-1.37%
-13.4%
Net Income, GAAP
15.16%
1.78%
5.82%
Sales/Revenue/Turnover
10.53%
7.13%
3.91%
Total Cash Common Dividend
10.36%
13.58%
9.09%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,345
10,541
10,598
11,395
42,879
2025
10,364
10,854
11,122
12,215
44,557
2026
11,005
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.48
4.05
4.27
4.79
16.58
2025
3.99
4.28
4.28
5.22
17.78
2026
4.44
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.39
0.39
0.39
1.53
2025
0.39
0.43
0.43
0.43
1.69
2026
0.44
- -
- -
- -
- -
Similar Companies
Epigenomics AG (EPGNY)
Prenetics Global Limited (PRE)
Joinn Laboratories(China)Co.,Ltd. (603127.SS)
Illumina, Inc. (0J8Z.L)
China Holdings, Inc. (CHHL)
Spermosens AB (SPERM.ST)
Business
Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, software, services, consumables, and reagents for research, analysis, discovery, and diagnostics worldwide. The company offers products including mass spectrometry systems, chromatography instruments, genetic analysis tools, bioprocessing equipment, clinical diagnostics assays, laboratory automation solutions, and electron microscopy technologies; its key brands encompass Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. Headquartered in Waltham, Massachusetts, Thermo Fisher was originally founded in 1902 through the merger of Fisher Scientific and Thermo Electron in 2006, and operates in over 70 countries serving pharmaceutical, biotechnology, academic, government, and healthcare customers across life sciences, analytical technologies, specialty diagnostics, and laboratory products segments. Recently, the company expanded its capabilities through the acquisition of Olink Holding AB in 2024 to bolster proteomics offerings, launched the new Orbitrap Astral mass spectrometer in late 2024 for high-throughput proteomics, and formed strategic partnerships including a multi-year collaboration with AstraZeneca to advance biomarker discovery; in 2025, Thermo Fisher announced expansions in gene editing technologies and sustainable manufacturing initiatives amid ongoing supply chain optimizations.

Company News

APIChat

  • reuters.com

    West Pharma names former Thermo Fisher executive Lagarde as CEO

  • businesswire.com

    Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026

  • zacks.com

    Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?

  • gurufocus.com

    Thermo Fisher Scientific Inc (TMO) Stock Up 6.8% and Still Undervalued -- GF Score: 83/100

  • businesswire.com

    Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies

  • gurufocus.com

    TMO Fairly Valued by DCF at $478

  • seekingalpha.com

    Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript

  • businesswire.com

    Thermo Fisher Scientific Announces Quarterly Dividend

  • businesswire.com

    Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day

  • gurufocus.com

    Amazon, McDonald Surge Into Jefferies Top Picks Broadcom as Gets Cut

  • finbold.com

    Jefferies updates its list of highest-conviction Buy-rated stocks

  • businesswire.com

    Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden

  • businesswire.com

    Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle

  • gurufocus.com

    TMO DCF Analysis: Intrinsic Value $478 vs Price $465

  • businesswire.com

    Thermo Fisher Scientific's Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials

  • zacks.com

    International Markets and Thermo Fisher (TMO): A Deep Dive for Investors

  • businesswire.com

    Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing

  • gurufocus.com

    TMO Fairly Valued by DCF at $478

  • businesswire.com

    Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies

  • businesswire.com

    Thermo Fisher Scientific to Host Investor Day